XNAS · Healthcare · Biotechnology
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.81 | -0.82 | -1.23% | $0 | ❌ Miss | -2.27% | +4.88% | — |
| 2026-05-11 | Q1 2026 | -0.65 | -0.93 | -43.08% | $0 | ❌ Miss | +0.75% | -15.84% | -11.82% |
| 2026-03-30 |
| Q4 2025 |
| -0.68 |
| -0.68 |
| +0.00% |
| — |
| ➖ Inline |
| +4.35% |
| +9.51% |
| +11.76% |
| 2025-11-10 | Q3 2025 | -0.54 | -0.67 | -24.07% | $0 | ❌ Miss | — | — | — |
| 2025-08-12 | Q2 2025 | -0.54 | -0.50 | +7.41% | $0 | ✅ Beat | +0.10% | +9.93% | +14.42% |
| 2025-03-27 | Q4 2024 | -0.29 | -0.39 | -34.48% | $0 | ❌ Miss | +0.00% | -11.72% | +10.52% |
Showing last 6 quarters.